Date: 2016-03-03
Type of information: Nomination
Compound: chief executive officer
Company: Autolus (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 3rd, 2016, Autolus announced that Dr Christian Itin will assume the role of chief executive officer with immediate effect. Dr Itin is a leader in the immuno-oncology field. Previously he served as president and CEO at Micromet, which was acquired in 2012 by Amgen. At Micromet, Dr Itin and his team pioneered the field of T-cell engaging antibodies, or BiTEs. The lead program, blinatumomab, obtained approval by the FDA as breakthrough therapy for the treatment of patients with acute lymphoblastic leukemia. Christian spent 13 years with Micromet in a number of senior management roles, becoming CEO in 2004. He continues to serve as Chairman of Autolus and Kuros Biosciences, and serves on the board of Kymab. From November 2012 to January 2016 he served as Chief Executive Officer and Chairman of Cytos Biotechnology. Dr Edward Hodgkin, Partner with Syncona, who has served as chief executive officer of Autolus since its inception in September 2014, will transition to a non-executive director role with immediate effect.
Financial terms:
Latest news:
Is general: Yes
